



*Small but heading for the big time*

## **Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology (ASCO)**

**Paris, France, 1 April, 2014 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.

The clinical trial will be presented during the congress session dedicated to sarcoma.

This year's ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties.

The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review.

Laurent Levy, CEO of Nanobiotix said: *"We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer."*

-Ends-

**About NANOBIOTIX - [www.nanobiotix.com](http://www.nanobiotix.com)**

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

**For more information, please contact:**

**Nanobiotix**

**Sarah Gaubert**

Head of Communication  
and Public Affairs

+33 (0)1 40 26 07 55

[contact@nanobiotix](mailto:contact@nanobiotix).

**NewCap.**

*Media (France)*

**Annie-Florence Loyer/ Nadège Le Lezec**

+33 (0)6 88 20 35 59

[afloyer@newcap.fr](mailto:afloyer@newcap.fr) / [nlelezec@newcap.fr](mailto:nlelezec@newcap.fr)

Financial communication  
and investors relations

**Louis-Victor Delouvrier / Emmanuel Huynh**

+33 (0)1 44 71 98 53

[lvdelouvrier@newcap.fr](mailto:lvdelouvrier@newcap.fr)

**Instinctif Partners - College Hill**

*Media relations (Outside France)* **Melanie Toyne**

**Sewell / Donia Al Saffar / Katherine Lynch**

+44 (0) 207 457 2020

[nanobiotix@instinctif.com](mailto:nanobiotix@instinctif.com)

***Disclaimer***

*This press release and the information contained therein do not constitute an offer of securities for sale or any solicitation to purchase or subscribe for Nanobiotix's shares in any jurisdiction. The distribution of this press release in certain jurisdictions may constitute a breach of applicable laws and regulations. Therefore, individuals who are located in such jurisdictions where this press release is issued, published or distributed must seek information and comply with such laws and regulations.*